| Generic name | Alemtuzumab |
| Pronunciation | ah-lem-TOOZ-i-mab |
| Brand name(s), other common name(s) | Campath® |
| Drug type | Monoclonal antibody |
| How the drug is given | Intravenously (IV) |
Indications and Usage
Alemtuzumab is FDA approved to treat people who have chronic lymphocytic leukemia (CLL).
Side effects needing medical attention
Fever or chills; cough or hoarseness; back, lower back or side pain; painful or difficult urination; bleeding or bruising; black, tarry stools; blood in urine or stools; pinhead-sized red spots on skin; diarrhea; dizziness; faintness, or lightheadedness when getting up from a lying or sitting position; headache; itching, hives or rash; nausea and vomiting; pale skin; shortness of breath; sore throat; sores, ulcers or white spots on lips or in mouth, or swelling or inflammation of the mouth; sudden sweating; swollen glands; tightness in chest; troubled breathing after exertion; unusual tiredness or weakness; wheezing; acid or sour stomach; bone pain; burning, crawling, itching, numbness, prickling, "pins and needles," or tingling feelings; lack or loss of strength; loss of appetite; muscle aches; painful cold sores or blisters on lips, nose, eyes or genitals; sleeplessness; stomach discomfort, upset or pain; weight loss.
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.